Artemisinin-based combination therapy for ... - The Cochrane Library

(... Continued)
Study or subgroup DHA-P AS+MQ Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Ashley 2004 THA 20/332 17/166 21.0 % 0.59 [ 0.32, 1.09 ]
Grande 2005 PER 37/252 26/251 26.3 % 1.42 [ 0.89, 2.27 ]
Subtotal (95% CI) 978 823 100.0 % 0.93 [ 0.67, 1.30 ]
Total events: 113 (DHA-P), 107 (AS+MQ)
Heterogeneity: Tau 2 = 0.05; Chi 2 = 5.22, df = 3 (P = 0.16); I 2 =43%
Test for overall effect: Z = 0.41 (P = 0.68)
5 Total Failure Day 63 PCR adjusted (losses to follow up included as successes)
Ashley 2003b THA 7/179 10/176 35.9 % 0.69 [ 0.27, 1.77 ]
Janssens 2003 KHM 4/215 6/230 23.7 % 0.71 [ 0.20, 2.49 ]
Ashley 2004 THA 6/332 8/166 31.3 % 0.38 [ 0.13, 1.06 ]
Grande 2005 PER 4/252 1/251 9.1 % 3.98 [ 0.45, 35.40 ]
Subtotal (95% CI) 978 823 100.0 % 0.67 [ 0.34, 1.33 ]
Total events: 21 (DHA-P), 25 (AS+MQ)
Heterogeneity: Tau 2 = 0.10; Chi 2 = 3.80, df = 3 (P = 0.28); I 2 =21%
Test for overall effect: Z = 1.14 (P = 0.25)
0.001 0.01 0.1 1 10 100 1000
Favours DHA-P Favours AS+MQ
Artemisinin-based combination therapy for treating uncomplicated malaria (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
135